anti-PD-L1 antibody · antibody

atezolizumab

27 active trials across 16 of our biomarkers, targeting PD-L1. 3 active approvals for a biomarker on marked.bio.

Also known as MPDL3280A, RG7446, Tecentriq.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Approvals and pivotal results

Biomarker-selected approvals in the United States and the European Union, with the pivotal trial's results and side effects where we have them. Results from different trials are not directly comparable.

Therapy	Biomarker	Tumour	United States	European Union
atezolizumab with cobimetinib + vemurafenib FDA, 2020 unresectable or metastatic, BRAF V600 mutation-positive Label 1.4: BRAF V600 mutation-positive. No EU equivalent. Year confirmed: FDA approval announced 30/07/2020. Source FDA, 2024 unresectable or metastatic, BRAF V600 mutation-positive Subcutaneous atezolizumab approved 12/09/2024 for all adult IV Tecentriq indications, including melanoma; label 1.4. Source Tecentriq, Tecentriq HybrezaBroader labelcobimetinib page vemurafenib page	BRAF V600E	melanoma	Approved 2020	Not approved
IMspire150 vs placebo + cobimetinib + vemurafenib, 514 randomised PFS 15.1 months vs 10.6 months, HR 0.78 (0.63-0.97) Trial details and side effects Patients first-line BRAF V600 melanoma (NCT02908672) Most common side effects rash, musculoskeletal pain, nausea, fatigue, hepatotoxicity, pyrexia Notes Atezolizumab added to cobimetinib and vemurafenib. From the FDA approval notice. Source FDA approval summary
atezolizumab with fluoropyrimidine + oxaliplatin FDA, 2026 adjuvant, stage III dMMR colon cancer, adults and children >=2 years FDA approval 08/10/2026; not yet on the DailyMed label (revised 5/2026). Source Tecentriq	MSI-H / dMMR	colon	Approved 2026	Not approved
ATOMIC vs mFOLFOX6 alone, 712 randomised DFS not reached vs not reached, HR 0.50 (0.35-0.73) Trial details and side effects Patients resected stage III dMMR colon cancer (NCT02912559) Notes Atezolizumab with mFOLFOX6, then atezolizumab. Disease-free survival. Approved 8 October 2026. Source US approval report

Biomarkers

Biomarker	Active trials	All trials	Furthest active phase
MSI-H / dMMR	8	14	Phase 2/3
BRAF V600E	6	13	Phase 2
BRCA1/2 mutation	5	7	Phase 2
KRAS G12C	4	5	Phase 2
EGFR exon 19 deletion / L858R	3	16	Phase 2
HER2 (ERBB2) activating mutation	3	3	Phase 3
PIK3CA activating mutation	3	4	Phase 1/2
ALK fusion	2	9	Phase 2
ROS1 fusion	2	2	Phase 2
FGFR2 fusion or rearrangement	1	4	Phase 2
KRAS G12D	1	2	Phase 2
NTRK1/2/3 fusion	1	2	Phase 2
RET fusion or mutation	1	3	Phase 2
FGFR3 alteration (mutation or fusion)	0	2	–
FLT3 mutation (ITD/TKD)	0	1	–
MET exon 14 skipping	0	1	–

Trials

27 of 60 trials shown

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Recruiting Phase 3 Boehringer Ingelheim Started 2026Primary completion 2032-02 NCT07195695

zongertinib FDApembrolizumabatezolizumabdurvalumabnivolumab

HER2 mutation: Documented Tyrosine kinase domain (TKD) activating Human epidermal growth factor recepto…

HER2 (ERBB2) activating mutationNon-small Cell Lung Cancer
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting Phase 2/3 Cancer Research UK Started 2023Primary completion 2029-10 NCT05770102

atezolizumab FDA

Confirmed diagnosis of a malignancy that is high TMB (defined as ≥10 mut/Mb), MSI-high or of proven (previously diagnosed) CMMRD disposition using an analytically validated nex…

MSI-H / dMMRMalignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

Active, not recruiting Phase 3 Exelixis Started 2022Primary completion 2026-06 NCT05425940

zanzalintinibatezolizumab FDAregorafenib

Documented NOT to have microsatellite instability-high (MSI-high) or mismatch repair deficient (dMMR) CRC by tissue-based analysis.

MSI-H / dMMRColorectal Cancer
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Active, not recruiting Phase 3 National Cancer Institute (NCI) Started 2018Primary completion 2027-06 NCT02997228

atezolizumab FDAbevacizumabfluorouracilleucovorinoxaliplatin

Tumor determined to be mismatch-repair deficient (dMMR) by Clinical Laboratory Improvement Act (CLIA)-certified immunohistochemical (IHC) …

MSI-H / dMMRMetastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Active, not recruiting Phase 3 National Cancer Institute (NCI) Started 2017Primary completion 2025-02 NCT02912559

atezolizumab FDAfluorouracilleucovorinoxaliplatin

Presence of deficient (d) DNA mismatch repair (dMMR)

MSI-H / dMMRColon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

Recruiting Phase 2 Sehhoon Park Started 2025Primary completion 2027-03 NCT06830694

atezolizumabetoposidecarboplatin

Patient initially diagnosed with activating EGFR mutation (L858R, Del 19) and treated with any kind of EGFR TKI.

EGFR exon 19 deletion / L858RSmall Cell Carcinoma of Lung
HTL0039732 in Participants With Advanced Solid Tumours

Recruiting Phase 1/2 Cancer Research UK Started 2023Primary completion 2028-12 NCT05944237

HTL0039732 Capsulesatezolizumab

MSS CRC with PIK3CA or HER2 mutation/genetic aberration, and/or other driver mutation/genetic aberration as agreed with the Sp…

PIK3CA activating mutationHER2 (ERBB2) activating mutationNeoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Recruiting Phase 2 German Cancer Research Center Started 2023Primary completion 2030-03 NCT05332561

atezolizumabinavolisibipatasertibolaparibsacituzumab govitecantrastuzumabpertuzumab

Arm 6 (Trastuzumab / Pertuzumab, ERBBB): HER2 exon-20 insertion, Activating HER2-mutation

HER2 (ERBB2) activating mutationBRCA1/2 mutationEarly-stage Breast Cancer
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Recruiting Phase 1/2 Maastricht University Medical Center Started 2023Primary completion 2027-02 NCT04954599

CP-506carboplatinipilimumabnivolumabpembrolizumabatezolizumabavelumabdurvalumabcemiplimab

BRCA1/2 carriers), dedicated HRD genomic assays (including exome-sequencing) from liquid or tissue biopsie…

BRCA1/2 mutationUnspecified Adult Solid Tumor, Protocol Specific
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2023Primary completion 2026-01 NCT05836584

atezolizumab FDAcapecitabinedocetaxelfluorouracilleucovorinoxaliplatin

…ically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma that is MSI-H/dMMR (microsatellite instability-high/mismatch repair deficient) as determined by one of …

MSI-H / dMMRClinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Active, not recruiting Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Started 2022Primary completion 2025-12 NCT05174650

atezolizumabderazantinib

Histologically documented diagnosis of non-resectable iCCA with positively confirmed FGFR2 fusion/rearrangement via NGS-Analysis.

FGFR2 fusion or rearrangementIntrahepatic Cholangiocarcinoma
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Active, not recruiting Phase 2 Georgetown University Started 2021Primary completion 2026-11 NCT04958811

tiragolumabatezolizumabbevacizumab

Confirmed activating alteration in EGFR (cohort B only)

EGFR exon 19 deletion / L858RNon-squamous Non-small-cell Lung Cancer
PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

Recruiting Phase 2 Samsung Medical Center Started 2021Primary completion 2025-12 NCT04819243

talazoparib FDA EUatezolizumab

Confirmed germline pathogenic BRCA1 and/or BRCA2 mutation or 35 HRD-related gene alterations (see Appendix 16.5)

BRCA1/2 mutationPremenopausal HR+/HER2- Metastatic Breast Cancer
Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

Active, not recruiting Phase 2 AIO-Studien-gGmbH Started 2021Primary completion 2027-04 NCT05118724

atezolizumab FDAIMM-101

Tumor is MSI-high (MSI-H) or MMR-deficient (dMMR) For the main study: assessed from biopsy or from resected…

MSI-H / dMMRColorectal Cancer
PLATFORM Study of Precision Medicine for Rare Tumors

Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2020Primary completion 2026-07 NCT04423185

aumolertinibdacomitinib FDA EUalectinibcrizotinibpyrotinibimatinibniraparibpalbociclibvemurafenibsintilimabatezolizumab

when obtaining EGFR mutation, ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation, BRAF mutation, BRCA1/2 mu…

EGFR exon 19 deletion / L858RBRAF V600EBRCA1/2 mutationALK fusionROS1 fusionRare Tumor
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Recruiting Phase 2 Roche Started 2020Primary completion 2026-11 NCT04302025

alectinibentrectinibvemurafenibcobimetinibpralsetinibatezolizumabSBRTChemotherapydivarasib

…on in ≥ 1% tumor cells as determined by Food and Drug Administration (FDA)-approved test, KRAS G12C mutation

KRAS G12CBRAF V600EALK fusionROS1 fusionRET fusion or mutationNTRK1/2/3 fusionNon-small Cell Lung Cancer
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Active, not recruiting Phase 2 Fondazione Melanoma Onlus Started 2020Primary completion 2023-12 NCT04722575

cobimetinib FDA EUvemurafenib FDA EUatezolizumab FDA

…urafenib, cobImetinib, and atezolizuMab in Patients With High-risk, Surgically Resectable BRAF Mutated and Wild-type Melanoma"

BRAF V600EMelanoma
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2018Primary completion 2025-07 NCT03600701

atezolizumabcobimetinib

Presence of a mutation in KRAS as detected by a Clinical Laboratory Improvement Act (CLIA)-approved assay is required fo…

KRAS G12CKRAS G12DMetastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
A Trial of Ipatasertib in Combination With Atezolizumab

Active, not recruiting Phase 1/2 Institute of Cancer Research, United Kingdom Started 2018Primary completion 2026-03 NCT03673787

ipatasertibatezolizumab

…other aberrations predicted to result in a hyperactivated PI3K-AKT pathway (eg activating mutations in PIK3CA, AKT1, AKT2) or PTEN loss (assessed by immunohistochemistry (IHC) (n=12).

PIK3CA activating mutationSolid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

Active, not recruiting Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Started 2018Primary completion 2027-05 NCT03421288

atezolizumab FDAfluorouracilleucovorinoxaliplatindocetaxel

…[and optional TMB/EBV\] must be performed locally and results for either of the following MSI-high, PD-L1 CPS≥1, TMB ≥10/MB or EBV+ must be available prior to randomization (for details, s…

MSI-H / dMMRGastric Cancer, Gastroesophageal Junction Adenocarcinoma
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2017Primary completion 2027-07 NCT03181100

atezolizumab FDAbevacizumabcobimetinib FDA EUnab-paclitaxelpaclitaxelvemurafenib FDA EU

ADDITIONAL INCLUSION CRITERIA FOR BRAF MUTATION (COHORT 1): Patients with a BRAFV600E mutation being considered for the triplet combination (vemurafenib + cobimetinib + atezol…

BRAF V600EMetastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2017Primary completion 2028-06 NCT03175432

atezolizumab FDAbevacizumabcobimetinib FDA EU

Patients that are known to have BRAFV600 mutation must have received prior BRAFi/MEKi prior to enrolling on TACo.

BRAF V600EBRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma, Metastatic Malignant Neoplasm in the Brain
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2017Primary completion 2026-06 NCT02849496

atezolizumabolaparib FDA EU

…d unresectable locally advanced or metastatic non-HER2-positive breast cancer and a known BRCA 1/2 mutation present

BRCA1/2 mutationAnatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

Active, not recruiting Phase 1 Roche Started 2023Primary completion 2027-07 NCT06496568

inavolisib FDA EUatezolizumab

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

PIK3CA activating mutationPIK3CA-Mutated Cancers
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Active, not recruiting Phase 1 Roche Started 2020Primary completion 2027-12 NCT04449874

divarasibatezolizumabcetuximabbevacizumaberlotinibGDC-1971inavolisib

Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.

KRAS G12CNon-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Active, not recruiting Phase 1 Amgen Started 2019Primary completion 2026-12 NCT04185883

sotorasib FDA EUtrametinibvociprotafibafatinibpembrolizumabpanitumumab FDAcarboplatinpemetrexeddocetaxelpaclitaxelatezolizumabpalbociclib

Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requireme…

KRAS G12CAdvanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Active, not recruiting Phase 1 Exelixis Started 2019Primary completion 2026-08 NCT03845166

zanzalintinibatezolizumab FDAavelumab

BRAF inhibitor (in combination with cetuximab +/- binimetinib) for subjects with BRAF V600E mutations

BRAF V600EMSI-H / dMMRNeoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

Completed Phase 3 Roche Started 2020 NCT04194203

atezolizumabbevacizumabpaclitaxelpemetrexedcarboplatin

…ecimen that is suitable for the determination of PD-L1 status, as well as the presence of EGFR mutations and ALK gene rearrangements, via central testing.

EGFR exon 19 deletion / L858RALK fusionCarcinoma, Non-Small-Cell Lung
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Unknown status Phase 3 Samsung Medical Center Started 2019 NCT03991403

atezolizumabpemetrexedbevacizumabcarboplatinpaclitaxelcisplatin

…dy of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

ALK fusionNon-small Cell Lung Cancer
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Withdrawn Phase 2 Roche Started 2024 NCT06331598

atezolizumab FDAtiragolumab

…ancer, head and neck cancer and any other tumor type with known high TMB (≥ 13 mut/MB) or MSI-H

MSI-H / dMMRSolid Tumors
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Withdrawn Phase 2 National Cancer Institute (NCI) Started 2023 NCT05564416

atezolizumaberdafitinib FDA EU

FGFR3 gene mutations (R248C, S249C, G370C, Y373C) or FGFR gene fusions (FGFR3-TACC3, FGFR3-BAIAP2L1, FGFR2-BIC…

FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementBladder Carcinoma, Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Renal Pelvis and Ureter Urothelial Carcinoma
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Terminated Phase 1/2 Affimed Started 2021 NCT05109442

AFM24atezolizumab

Subjects must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulation fr…

EGFR exon 19 deletion / L858RAdvanced Solid Tumor
CRAFT: The NCT-PMO-1602 Phase II Trial

Completed Phase 2 German Cancer Research Center Started 2021 NCT04551521

vemurafenib FDA EUcobimetinib FDA EUatezolizumab FDAtrastuzumabpertuzumabalectinibipatasertibinavolisib

Arm 1 (BRAF V600E/K): BRAF V600E/K mutation

BRAF V600EPIK3CA activating mutationALK fusionRET fusion or mutationMSI-H / dMMRMetastatic or Locally Advanced Malignancies
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Terminated Phase 1/2 M.D. Anderson Cancer Center Started 2021 NCT04902040

atezolizumab FDAavelumabdurvalumab FDA EUnivolumab FDA EUpembrolizumab FDA EUPlinabulin

…, renal cell cancer, bladder cancer, Merkle cell cancer, microsatellite instability high (MSI-H) cancer (any histology), and melanoma) progressed on previous anti-PD-1/PD-L1 mAb treatme…

MSI-H / dMMRAdvanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Terminated Phase 2 Duke University Started 2020 NCT04099836

atezolizumabbevacizumab

…n of primary lung carcinoma, non-squamous histology with EGFR exon deletion 19 or exon 21 L858R mutation

EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Terminated Phase 2 Fundación GECP Started 2020 NCT04512430

atezolizumabbevacizumabcarboplatinpemetrexed

Sensitizing EGFR mutation (Del Exon 19 and ins Exon 21).

EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer, EGFR Gene Mutation
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Completed Phase 2 ETOP IBCSG Partners Foundation Started 2020 NCT04245085

atezolizumabbevacizumabcarboplatinpaclitaxelpemetrexed

…own EGFR mutations genotypes by tissue or ctDNA, patients with common mutations (L858R or Del19) and other rare mutations (e.g.

EGFR exon 19 deletion / L858REGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Completed Phase 2 Roche Started 2020 NCT04426825

atezolizumabbevacizumab

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Completed Phase 2 National Taiwan University Hospital Started 2020 NCT04147351

atezolizumabbevacizumab

Stage IIIB\~IV NSCLC with known EGFR activating mutation not amenable to curative surgery or radiotherapy.

EGFR exon 19 deletion / L858RNSCLC Stage IIIB~IV
Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

Terminated Phase 1/2 Columbia University Started 2020 NCT04214418

cobimetinibhydroxychloroquineatezolizumab

…une Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

KRAS G12CKRAS G12DNTRK1/2/3 fusionMSI-H / dMMRGastrointestinal Cancer
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Completed Phase 2 Centre Francois Baclesse Started 2019 NCT04042558

carboplatinpemetrexedatezolizumabbevacizumab

…Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

EGFR exon 19 deletion / L858RALK fusionNSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation, ALK Gene Rearrangement Positive
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Completed Phase 1/2 Astellas Started 2019 NCT03730012

gilteritinib FDA EUatezolizumab

Subject is positive for FLT3 mutation in bone marrow or blood after completion of the subject's last interventional treatment.

FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Derazantinib and Atezolizumab in Patients With Urothelial Cancer

Completed Phase 1/2 Basilea Pharmaceutica Started 2019 NCT04045613

derazantinibatezolizumab

Documented central FGFR genetic aberration (FGFR1, FGFR2, or FGFR3 mutations / short variants and rearrangements / fusions) (Note

FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementUrothelial Carcinoma
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Completed Phase 2 SCRI Development Innovations Started 2019 NCT03977467

atezolizumab FDAtiragolumab

MSI-high solid tumors as defined by local testing for MSI/MMR will also be included.

MSI-H / dMMRNon-Small Cell Lung Cancer, Solid Tumor
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Unknown status Phase 2 The University of Hong Kong Started 2018 NCT03647956

atezolizumabbevacizumabcarboplatinpemetrexed

Stage IIIB or IV NSCLC with known EGFR activating mutation not amenable to curative surgery or radiotherapy.

EGFR exon 19 deletion / L858RNSCLC Stage IIIB, NSCLC Stage IV, EGFR Activating Mutation
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Completed Phase 2 Roche Started 2018 NCT03625141

cobimetinib FDA EUatezolizumab FDAvemurafenib FDA EU

…th Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

BRAF V600EMetastatic Melanoma
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Completed Phase 2 University College, London Started 2017 NCT02314481

atezolizumab FDAvemurafenib FDA EUalectinibtrastuzumab emtansine

Arm 2: Presence of BRAFV600 mutation

BRAF V600EALK fusionRET fusion or mutationNon-small Cell Lung Cancer
A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Terminated Phase 1/2 Clovis Oncology Started 2016 NCT02630186

rociletinibatezolizumab

…cally advanced or metastatic NSCLC, with one or more activating EGFR mutation (eg, G719X, exon 19 deletion, L858R, L861Q) and absence of exon 20 insertion

EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours

Completed Phase 2 Gustave Roussy, Cancer Campus, Grand Paris Started 2016 NCT02992912

atezolizumab

Patients EGFR-mutant can be included only if they have been treated with, or developed toxicity with or refuse…

EGFR exon 19 deletion / L858RPatients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )
Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Completed Phase 2 University Hospital, Essen Started 2016 NCT02902029

vemurafenib FDA EUcobimetinib FDA EUatezolizumab FDA

…by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

BRAF V600EMalignant Melanoma
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Completed Phase 2 Roche Started 2014 NCT02091141

trastuzumabpertuzumaberlotinibvemurafenib FDA EUcobimetinib FDA EUVismodegibalectinibatezolizumab FDA

…esting results from CLIA-certified laboratories (using tissue and/or blood) demonstrating BRAF V600 mutations a) For participants screened using a blood assay: obtain tissue-based testing r…

BRAF V600EALK fusionNeoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Withdrawn Phase 1 M.D. Anderson Cancer Center Started 2023 NCT05510427

infigratinibatezolizumabbevacizumab

Has FGFR2 fusion in tumor tissue.

FGFR2 fusion or rearrangementCholangiocarcinoma, Liver Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated Phase 1 Fate Therapeutics Started 2022 NCT05395052

FT536cyclophosphamidefludarabineIL-2avelumabpembrolizumabnivolumabatezolizumabtrastuzumabcetuximabamivantamab

mesenchymal-epithelial transition (MET) exon 14 skipping mutation that has progressed on or intolerant of at least one prior line of MET …

MET exon 14 skippingNon Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

Completed Phase 1 Nykode Therapeutics ASA Started 2021 NCT05018273

atezolizumab FDA

…umor types: melanoma, NSCLC, RCC, UC, HNSCC, TNBC, gastric/GEJ cancer, cervical, anal, or MSI-high tumors.

MSI-H / dMMRSolid Tumors, Adult
Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

Completed Phase 1 Regeneron Started 2018 NCT03438318

CMP-001atezolizumab

Participants with epidermal growth factor (EGFR) activating mutations, EGFR T790M or anaplastic lymphoma kinase (ALK) gene re-arrangement must have received p…

EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Terminated Phase 1 Mayo Clinic Started 2018 NCT03455556

Anetumab Ravtansineatezolizumab FDA

…rug Administration (FDA) approved agents targeting these aberrations (ie EGFR, ALK, ROS1, BRAF V600E)

BRAF V600EMesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Completed Phase 1 Roche Started 2017 NCT03101280

atezolizumabrucaparib FDA

…LY, have a deleterious germline or somatic breast cancer susceptibility gene 1 (BRCA1) or BRCA2 mutation or tumors that are wild-type BRCA but show high levels of loss of heterozygosity (LOH) (t…

BRCA1/2 mutationGynecologic Neoplasms
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Completed Phase 1 Roche Started 2014 NCT02013219

alectinibatezolizumaberlotinib FDA EU

Participants in Stage 2 (Expansion) receiving erlotinib: i) sensitizing mutation in the EGFR gene and ii) consent to collection of tumor tissue samples before, during, and after trea…

EGFR exon 19 deletion / L858RALK fusionNon-Small Cell Lung Cancer
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Completed Phase 1 Roche Started 2012 NCT01656642

atezolizumab FDAcobimetinib FDA EUvemurafenib FDA EU

…ologic or cytologic documentation of metastatic or Stage IIIc unresectable melanoma, with BRAFV600 mutation as assessed by BRAFV600 Mutation Test.

BRAF V600EMalignant Melanoma
SMMART Adaptive Clinical Treatment (ACT) Trial

Withdrawn Early Phase 1 OHSU Knight Cancer Institute Started 2023 NCT05238831

alectinibalpelisibanastrozoleatezolizumabbevacizumab FDA EUcapecitabinecarboplatincobimetinibentrectiniberibulinfulvestrantpertuzumab

… least one prior line of therapy with a PARP inhibitor for triple negative disease with a BRCA1/2 mutation.

BRCA1/2 mutationAdvanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma

Approvals and pivotal results

Biomarkers

Sponsors

Trials